Page 197 - Read Online

Glinsky Genetic signatures of lethal disease in early stage prostate cancer

8. DeFrances CJ, Lucas CA, Buie VC, Golosinskiy A. 2006 National 15. Glinskii AB, Ma J, Ma S, Grant D, Lim CU, Sell S, Glinsky GV.
Hospital Discharge Survey. Natl Health Stat Report 2008;(5):1-20. Identification of intergenic trans-regulatory RNAs containing a
9. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, disease-linked SNP sequence and targeting cell cycle progression/
Schröder FH, de Koning HJ. Lead times and overdetection due to differentiation pathways in multiple common human disorders. Cell
prostate-specific antigen screening: estimates from the European Cycle 2009;8:3925-42.
Randomized Study of Screening for Prostate Cancer. J Natl Cancer 16. Glinskii AB, Ma S, Ma J, Grant D, Lim CU, Guest I, Sell S, Buttyan
Inst 2003;95:868-78. R, Glinsky GV. Networks of intergenic long-range enhancers and
10. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen snpRNAs drive castration-resistant phenotype of prostate cancer and
V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, contribute to pathogenesis of multiple common human disorders. Cell
Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard Cycle 2011;10:3571-97.
X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen 17. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies
A; ERSPC Investigators. Screening and prostate-cancer mortality in a a death-from-cancer signature predicting therapy failure in patients
randomized European study. N Engl J Med 2009;360:1320-8. with multiple types of cancer. J Clin Invest 2005;115:1503-21.
11. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, 18. Glinsky GV, Higashiyama T, Glinskii AB. Classification of human
Pihl CG, Stranne J, Holmberg E, Lilja H. Mortality results from the breast cancer using gene expression profiling as a component of the
Göteborg randomised population-based prostate-cancer screening survival predictor algorithm. Clin Cancer Res 2004;10:2272-83.
trial. Lancet Oncol 2010;11:725-32.
12. Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson 19. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL.
J, Hugosson J; National Prostate Cancer Register (NPCR) of Gene expression profiling predicts clinical outcome of prostate cancer.
Sweden. Outcomes in localized prostate cancer: National Prostate J Clin Invest 2004;113:913-23.
Cancer Register of Sweden follow-up study. J Natl Cancer Inst 20. Glinsky GV, Krones-Herzig A, Glinskii AB, Gebauer G. Microarray
2010;102:950-8. analysis of xenograft-derived cancer cell lines representing multiple
13. Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, experimental models of human prostate cancer. Mol Carcinog
Walsh PC, Carter HB. Active surveillance program for prostate 2003;37:209-21.
cancer: an update of the Johns Hopkins experience. J Clin Oncol 21. Varma S, Simon R. Bias in error estimation when using cross-
2011;29:2185-90. validation for model selection. BMC Bioinformatics 2006;7:91.
14. Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y, 22. Tavazoie S, Hughes JD, Campbell MJ, Cho RJ, Church GM.
Perner S, Adami HO, Fall K, Mucci LA, Kantoff PW, Stampfer M, Systematic determination of genetic network architecture. Nat Genet
Andersson SO, Varenhorst E, Johansson JE, Gerstein MB, Golub 1999;22:281-5.
TR, Rubin MA, Andrén O. Molecular sampling of prostate cancer: 23. Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM. Increasing
a dilemma for predicting disease progression. BMC Med Genomics incidence of metastatic prostate cancer in the United States (2004-
2010;3:8. 2013). Prostate Cancer Prostatic Dis 2016;19:395-7.

Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ September 21, 2017 189